Patent intelligence · EP
EP 1938801
Nanoemulsion
Nanoemulsion
Patent details — EP 1938801
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Jul 2, 2008
- Expiration
- Jun 27, 2028
- Applicant
- BIOFRONTERA BIOSCIENCE GMBH [DE]
- CPC classes
- A61K 9/ 12 A I, A61K 9/ 107 A I, A61K 31/ 195 A I, A61K 47/ 10 A I
Quick answer
EP 1938801 (Nanoemulsion) is held by BIOFRONTERA BIOSCIENCE GMBH [DE]. Status: granted. Granted Jul 2, 2008. Expires Jun 27, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOFRONTERA BIOSCIENCE GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 12 A I, A61K 9/ 107 A I, A61K 31/ 195 A I, A61K 47/ 10 A I, A61K 47/ 44 A I, A61K/806
More from BIOFRONTERA BIOSCIENCE GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
US 20260108463
NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION
granted -
US 2024335360
PRESSURIZED NANOEMULSION
granted -
WO 2024209065
NANOÉMULSION SOUS PRESSION
granted -
WO 2024209064
NANOÉMULSION SANS PROPYLÈNE GLYCOL
granted -
US 2024335380
NANOEMULSION WITHOUT PROPYLENE GLYCOL
granted -
US 2021315993
PHOTODYNAMIC THERAPY COMPRISING TWO LIGHT EXPOSURES AT DIFFERENT WAVELENGTHS
granted -
WO 2014117863
FORMES POLYMORPHES DE SELS D'ADDITION D'ACIDE DE THIOXANTHÈNE-9-YLIDÈNE-1-MÉTHYLPIPÉRIDINES UTILISÉS COMME COMPOSÉS ANTIMIGRAINEUX
granted -
DE 202010004750
Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
granted
Frequently asked questions
What is US patent 1938801?
EP 1938801 (Nanoemulsion) is held by BIOFRONTERA BIOSCIENCE GMBH [DE]. Status: granted. Granted Jul 2, 2008. Expires Jun 27, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 1938801?
BIOFRONTERA BIOSCIENCE GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does EP 1938801 expire?
Our index shows an expiration date of Jun 27, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.